ARGX

Rating neutralAI Memo

argenx SE

As of 2026-10-09/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-09 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

EMPASSION MMN readout tests a second pipeline asset • 2026-12-31

Base target: $840 / p=50% prob

Biggest risk

An independent committee recommended stopping Phase 3 UNITY for futility; argenx said the study cannot meet its Sjögren's primary endpoint. That removes a potential VYVGART label expansion. Fierce Pharma reported that William Blair had modeled $1.4 billion in peak sales for the indication before the setback; this is an analyst projection, not company guidance. No verified post-announcement target or estimate revisions were available. [#PR-2026-10-08-UNITY] Company release Analyst coverage

Invalidation

Break below $620 or thesis failure.

What would change my mind?

The existing VYVGART franchise remains substantial: second-quarter product sales were $1.5 billion, up 60% year over year. Positive ALKIVIA Phase 3 myositis results and FB102 Phase 2 celiac results preserve distinct expansion paths despite UNITY. [#PR-2026-07-23] Company results [#PR-2026-08-17] ALKIVIA release [#PR-2026-10-08-FB102] FB102 release

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-09

Base target

$840

p=50%

Bull target

$1020

p=25%

Bear target

$620

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

October 22 commercial update tests VYVGART growth
FB102 Phase 3 development plan after celiac Phase 2 success
The existing VYVGART franchise remains substantial: second-quarter product sales were $1.5 billion, up 60% year over year.

BearKey bullets

ALKIVIA's dermatomyositis subgroup showed a similar effect magnitude but did not reach statistical significance, creating label-scope uncertainty.
[#PR-2026-08-17] Company release
Commercial concentration in VYVGART and rising R&D spending heighten sensitivity to uptake or further trial disappointments.

WatchKey bullets

EMPASSION MMN readout tests a second pipeline asset

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $840 (p=50%)

Target spread vs base: +21% / -26%

Scenario probabilities

Bull Target: $1020 (p=25%)Base Target: $840 (p=50%)Bear Target: $620 (p=25%)

Commentary

The October 8 close was down 11.83%, consistent with the market prioritizing UNITY futility over same-day positive FB102 data. News tone is negative despite continued commercial growth. The social, options, short-interest, and employee figures are unavailable in the packet; zero entries above mean unavailable, not neutral measurements. Verified post-event analyst target revisions were also unavailable. October 8 close [#PR-2026-10-08-UNITY] UNITY release [#PR-2026-10-08-FB102] FB102 release

As of 2026-10-09 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

October 22 commercial update tests VYVGART growth
FB102 Phase 3 development plan after celiac Phase 2 success

Scenarios

Bull Target (Scenario probability)

$1020 / p=25% prob

Base Target (Scenario probability)

$840 / p=50% prob

Bear Target (Scenario probability)

$620 / p=25% prob

Analysis 2026-10-09 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.40

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
EMPASSION MMN readout tests a second pipeline asset
argenx expects fourth-quarter 2026 topline results from the registrational EMPASSION study of empasiprubart in multifocal motor neuropathy. A positive result could diversify the pipeline beyond efgartigimod; failure would compound the October UNITY setback. [#PR-2026-07-23] Company results
Prob 55.00% • Move 10.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

October 22 commercial update tests VYVGART growth
2026-10-22
argenx scheduled third-quarter results for October 22. The decision-relevant measure is whether VYVGART sales sustain momentum after second-quarter product sales reached $1.5 billion, up 60% year over year. This is a commercial-uptake test, not an assumed earnings beat. [#PR-2026-07-23] Company results
Prob 70% • Move 6% • Priced-in 45%

Long-term Catalysts

Months to a year

FB102 Phase 3 development plan after celiac Phase 2 success
2027-06-30
FB102 met its Phase 2 celiac primary endpoint during a gluten challenge (p=0.0176), and argenx plans Phase 3 development. Trial design and timing have not been announced; the date here is a monitoring estimate, not company guidance. Phase 2 results do not establish Phase 3 success. [#PR-2026-10-08-FB102] Company release
Prob 60% • Move 8% • Priced-in 30%

Risks

ALKIVIA's dermatomyositis subgroup showed a similar effect magnitude but did not reach statistical significance, creating label-scope uncertainty. [#PR-2026-08-17] Company release
Commercial concentration in VYVGART and rising R&D spending heighten sensitivity to uptake or further trial disappointments. [#PR-2026-07-23] Company results
FB102's positive Phase 2 result may not replicate in Phase 3, and its development timetable is unconfirmed. [#PR-2026-10-08-FB102] Company release
UNITY futility eliminates the current Sjögren's Phase 3 expansion path; full study analysis remains pending. [#PR-2026-10-08-UNITY] Company release

Peers

Symbol	Summary
IMVT	Direct development-stage FcRn comparator: Immunovant is testing IMVT-1402 in potentially registrational myasthenia gravis and CIDP studies, overlapping VYVGART's core diseases. Its Sjögren's study also makes the UNITY setback relevant to class sentiment, but ARGX's marketed franchise and IMVT's pre-commercial profile make valuation multiples non-comparable. Immunovant update
JNJ	Direct gMG product competitor, not a close company valuation peer: Johnson & Johnson's approved FcRn blocker IMAAVY competes for treatment decisions, and its EPIC head-to-head study against another FcRn blocker is enrolling. JNJ's diversified earnings limit any inference from its stock multiple to ARGX. J&J clinical update
UCB	Direct commercial gMG competitor: UCB markets RYSTIGGO for adults who are AChR- or MuSK-antibody positive. Comparing uptake and eligible populations with VYVGART is relevant, while UCB's broader portfolio makes company-wide multiples a loose valuation reference. UCB product information

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-09

Loading AI feed…

Symbol

Summary

IMVT

Direct development-stage FcRn comparator: Immunovant is testing IMVT-1402 in potentially registrational myasthenia gravis and CIDP studies, overlapping VYVGART's core diseases. Its Sjögren's study also makes the UNITY setback relevant to class sentiment, but ARGX's marketed franchise and IMVT's pre-commercial profile make valuation multiples non-comparable. Immunovant update

JNJ

Direct gMG product competitor, not a close company valuation peer: Johnson & Johnson's approved FcRn blocker IMAAVY competes for treatment decisions, and its EPIC head-to-head study against another FcRn blocker is enrolling. JNJ's diversified earnings limit any inference from its stock multiple to ARGX. J&J clinical update

UCB

Direct commercial gMG competitor: UCB markets RYSTIGGO for adults who are AChR- or MuSK-antibody positive. Comparing uptake and eligible populations with VYVGART is relevant, while UCB's broader portfolio makes company-wide multiples a loose valuation reference. UCB product information